ALFA Finder| Revenue guidance | 15.0% → 20.0% Raised by 5.0 percentage points |
|---|---|
| Management target | Revenue 15.0% FY27 |
| Revenue growth | 20% YoY growth in Q1FY27. |
|---|---|
| Margins | Gross margin at 65%; Adjusted EBITDA margin improved to 28%. |
| Order book | Strengthened by new orphan drug program in Europe and GLP-1 contracts. |
| Demand visibility | Strong visibility from new CDMO contracts and 55 SKU technology transfer. |
| Management confidence | High, citing strong CDMO pipeline and strategic contract wins. |
Growth
Revenue grew 20% YoY to INR 18,003 million; PAT surged 47% to INR 3,170 million.
Outlook
Management raised near-term growth outlook from 15% to 20% CAGR. INR 2,000 crore capex program remains on track.
Risks
Supply disruptions in Saudi Arabia and delays in NUPCO tender awards impacted Rest of World performance.
Last quarter's promises, checked
Delivered
- Guided 12-13% revenue growth → delivered 20% (= BEAT)
- Guided 25-26% EBITDA margin → delivered 28% (= BEAT)
- Guided INR 2,000cr capex program → on track (= DELIVERED)
Partly delivered
- Guided RoW stability → impacted by Saudi supply disruptions (= PARTIAL)
Investor Presentation filed with BSE, NSE: GLAND. Summary written with AI assistance from the document.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,263.90
- Market cap
- ₹53,858 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 43.6×Sector 43.8×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Annual General Meeting
Gland Pharma's shareholders approved the appointment of Xingli Wang as Non-Executive Non-Independent Director via postal ballot. The ordinary resolution passed with 97.07% of votes in favour.
Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.